Articles related to OCULAR HYPERTENSION

The FDA classified a recall of dorzolamide and timolol ophthalmic solution as a Class II event after reports of defective containers, affecting a specific lot used to treat glaucoma and ocular hypertension.

Systemic nicotinamide exposure was associated with a lower risk of conversion from ocular hypertension to primary open-angle glaucoma in a large real-world cohort. Patients receiving nicotinamide also had lower rates of topical therapy initiation and laser trabeculoplasty, although the study did not establish causality.

A young hyperopic patient developed prolonged acute angle-closure glaucoma after an initial misdiagnosis, leading clinicians to pursue an anatomy-based surgical approach when laser iridotomy alone failed to provide sustained pressure control.

The FDA granted 510(k) clearance for a wireless-enabled pressure-modulating goggle system designed to reduce nocturnal intraocular pressure in adults with open-angle glaucoma, with availability expected in Q4 2026.

A case-control study identified covert mortality nodavirus, previously known only in aquatic animals, in iris tissue of patients with persistent ocular hypertensive viral anterior uveitis, with exposure risk concentrated among those who handle or consume raw aquatic animals daily.

Explore the recommendations for functional glaucoma testing from the World Glaucoma Association, an essential tool for optometrists in the detection and follow-up of this common condition. Learn how these recommendations can improve patient care and outcomes.